Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30454467 | 1.00 | HTR2C (0.52) | HTR2CHTR2AHTR3EHTR3BHTR3A | |
| SCHEMBL22391864 | 0.77 | PTGDR2 (0.44) | HTR2CHTR2AHTR2BDPP4 | |
| SCHEMBL30454657 | 0.77 | PTGDR2 (0.44) | HTR2CHTR2AHTR2BDPP4 | |
| SCHEMBL30454533 | 0.74 | GLP1R (0.37) | HTR2CHTR2ATRPA1 | |
| SCHEMBL29016266 | 0.72 | HTR2C (0.49) | HTR2CHTR2AHTR3EHTR3BHTR3A | |
| SCHEMBL22392142 | 0.72 | HTR1A (0.40) | HTR2CHTR2AHTR3EHTR3BHTR3A | |
| SCHEMBL30454719 | 0.72 | HTR1A (0.40) | HTR2CHTR2AHTR3EHTR3BHTR3A | |
| SCHEMBL20288052 | 0.70 | HTR3A (0.51) | HTR2CHTR2AHTR3EHTR3BHTR3A | |
| SCHEMBL13533076 | 0.69 | HTR2C (0.54) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL28973080 | 0.69 | HTR3A (0.50) | HTR2CHTR2AHTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12365670-B2 | GLP-IR agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| CN-113227068-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| CN-113227068-A | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | HTR2C 1375/4885HTR2A 1546/4885HTR3E 1825/4885 |
| US-10844049-B2 | GLP-1R agonists and uses thereof | GLP1R, GPR119, GIPR | HTR2C 558/4885HTR2A 441/4885HTR3E 453/4885 |
| US-12365670-B2 | GLP-IR agonists and uses thereof | GLP1R, GPR119, GIPR | HTR2C 815/4885HTR2A 638/4885HTR3E 814/4885 |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | HTR2C 558/4885HTR2A 441/4885HTR3E 453/4885 |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | HTR2C 644/4885HTR2A 474/4885HTR3E 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.